Study objectives: Prior to the availability of the oral endothelin antagonist bosentan, most patients with pulmonary arterial hypertension (PAH) were treated with continuously infused ...

Because of its chemical instability (metabolic half-life of one to two minutes), epoprostenol sodium is supplied as a powder with a sterile diluent and must be reconstituted by the patient and ...

They were given long term intravenous prostaglandin treatment (either epoprostenol (n = 61) or iloprost (n = 13)) or conventional treatment with oral anticoagulants (n = 24) with or without calcium ...

Objectives To characterise the safety and tolerability of nintedanib and the dose adjustments used to manage adverse events in patients with systemic sclerosis-associated interstitial lung disease ...

Prostacyclin analogs are a standard long-term treatment for severe PAH. Flolan (epoprostenol) was the first drug in this class. It is used in severe cases if other treatments aren’t working well ...

15,16 “In patients with PAH initiating therapy with IV epoprostenol, we suggest against the routine simultaneous initiation of bosentan.” (Ungraded consensus-based statement 7) “For WHO FC III or IV ...

Background Pulmonary hypertension (PHT) lacks community prevalence and outcome data. Objective To characterise minimum ‘indicative’ prevalences and mortality data for all forms of PHT in a selected ...

The mechanism of thrombocytopenia during acute pulmonary hypertension (PH) decompensation may be partly due to platelet aggregation in the lung. Platelet aggregates in explanted lung from 16 lung ...